-
Jan 27, 2021 09:33 AM IST In the longer term, what we like about Rossari Biotech is that it's led by technocrats with strong domain knowledge, which in turn has helped in superior execution of capex projects in the past and diversification into new end-markets
-
Nov 25, 2020 12:29 PM IST Rossari Biotech is confident of doubling sales in 3-4 years, and the home and personal care category is expected to comprise over half of the company's revenues in the coming quarters, says its co-founder and MD
-
Oct 29, 2020 09:44 AM IST -
Oct 27, 2020 06:33 PM IST -
Oct 27, 2020 11:20 AM IST Rossari Biotech reported profit after tax (PAT) of Rs 20.7 crore in Q2FY21, higher than Rs 17.7 crore reported in the same period last year.
-
Oct 27, 2020 09:42 AM IST Rossari Biotech's growth is likely to be led by performance chemicals business in the medium term
-
Sep 02, 2020 01:20 PM IST Smart investors would look for dark horses in this segment which will do the ‘catch-up’ over the next few quarters.
-
Aug 25, 2020 10:41 AM IST While Rossari Biotech has proven to be a strong beneficiary of the opportunity for chemical cleanliness solutions, its valuation is well ahead of fundamentals in our view
-
Jul 23, 2020 09:20 PM IST The stock opened with a premium of Rs 245, or 58 percent, on the BSE against its issue price of Rs 425 per share, and rose to Rs 710 intraday, i.e. 67.1 percent higher
-
Jul 23, 2020 08:12 PM IST Plutus Wealth Management bought 4,77,637 shares in the company at Rs 669.25 per share.
-
Jul 23, 2020 06:22 PM IST Rossari Biotech is among top 11 companies that showed remarkable performance, listing at a premium of over 50 percent in last five years.
-
Jul 23, 2020 01:57 PM IST Astha Jain, Senior Research Analyst at Hem Securities also said if the stock lists at more than 40 percent premium then investors are advised to book partial profit.
-
Jul 23, 2020 10:03 AM IST The listing premium was much higher than the grey market premium (of around Rs 160-180 per share) as well as analysts' expectations of Rs 130-175 per share.
-
Jul 22, 2020 06:09 PM IST Rossari Biotech's public issue that consisted a fresh issue of Rs 50 crore and offer for sale of 1.05 crore equity shares by promoters closed with 79.37 times subscription on July 15
-
Jul 21, 2020 01:08 PM IST The equity shares received in the allotment are expected to be credited to DP accounts on July 22 and the listing of shares is likely to take place on July 23.
-
Jul 20, 2020 12:52 PM IST As FII inflows continue to remain strong, the liquidity remains healthy and hence sharper correction without a specific event trigger on domestic/global seems unlikely.
-
Jul 17, 2020 03:09 PM IST Ajcon Research Rossari Biotech Started in CY03 as “Rossari Lab tech”, a partnership firm, Rossari was converted to Company in CY09 by Mr. Edward Menezes and Mr. Sunil Chari.
-
Jul 15, 2020 11:58 AM IST The public issue consists of a fresh issue of Rs 50 crore and an offer for sale of 1.05 crore equity shares by its promoters Edward Menezes and Sunil Chari.
-
Jul 14, 2020 02:40 PM IST In past 3 years (FY17-FY20), company has delivered stupendous growth on revenue, EBITDA and net profit level, which grew at a CAGR of 42 percent, 57 percent and 60 percent respectively.
-
Jul 13, 2020 06:07 PM IST Emkay Global Financial Rossari Biotech is planning to raise ~Rs4.95bn through a mix of fresh issue (Rs500mn, 1.17mn shares) combined with Offer for Sale (OFS) route (~Rs4.45bn, 10.5mn shares), to the public.
-
Jul 13, 2020 05:47 PM IST Motilal Oswal Hence, investors can Subscribe the IPO from a long term perspective.
-
Jul 13, 2020 05:31 PM IST Ventura Securities Rossari Biotech (Rossari) is one of the leading specialty chemicals manufacturing company in India, catering to various customer needs across FMCG, apparel, and poultry and animal feed industries.
-
Jul 13, 2020 05:16 PM IST Mehta Equities has come out with its report on Rossari Biotech. The research firm has recommended to "Subscribe'' the IPO in its research report as on July 10, 2020
-
Jul 13, 2020 05:14 PM IST Arihant Capital has come out with its report on Rossari Biotech. The research firm has recommended to "Subscribe'' the IPO in its research report as on July 10, 2020
-
Jul 13, 2020 05:13 PM IST Hem Securities has come out with its report on Rossari Biotech. The research firm has recommended to "Subscribe'' the IPO in its research report as on July 10, 2020